Animal Model Market by Animal Type (Rat, Mice, Guinea Pigs, Rabbits, and Others), Application (Drug Discovery & Development, Basic Research, and Others), and End User (Pharma & Biotech Companies, Academic Research Institutes, and Others): Global Opportunity Analysis and Industry Forecast, 2021–2030
The global animal model market was valued at $1,469 million in 2020, and is projected to reach $2,677 million by 2030, registering a CAGR of 6.1% from 2021 to 2030.
The animal in which biological and pathological studies are done & tested is known as an animal model. Animal models are utilized as they have functional similarity to the human body. They are used to study the development & advancement of various diseases and test new treatment methods before conducting human trials. However, there are several animal welfare guidelines that have to be followed while using animal models for experiments. There are different types of animals used as animal models such as rat, mice, guinea pigs, rabbits, and others.
The growth of the animal model market is driven by rise in demand for personalized medicines, increase in development of humanized mouse models, surge in initiatives by government organizations in various academic & research institutions, and increase in number of pharmaceutical R&D activities. In addition, emergence of CRISPR as a powerful technology in the field of biomedical research, increase in need of animal models for production & quality control for therapeutic purpose, rise in use of animal models in biomedical research, toxicology, physiology, cancer research, neurological research, genetic research, & xenotransplantation further boost the growth of the market. Moreover, use of animal model aids in validation & target identification, drug screening & lead optimization, toxicity & safety screening, and in preclinical analyses of drug safety & efficacy, which drive the growth of the market. However, regulations and laws for ethical use of animals in research are expected to restrain the growth of the animal model market. Conversely, growth opportunities in emerging markets are expected to offer lucrative opportunities during the forecast period.
The animal model market is segmented into animal type, application, end user, and region. On the basis of animal type, the market is categorized into rat, mice, guinea pigs, rabbits, and others. By application, the market is divided into drug discovery & development, basic research, and others. The drug discovery & development segment is further segmented by animal type such as rat, mice, guinea pigs, rabbits, and others. The basic research segment is further segmented by animal type such as rat, mice, guinea pigs, rabbits, and others. The others segment is further fragmented by animal type such as rat, mice, guinea pigs, rabbits, and others. By end user, the market is segregated into pharma & biotech companies, academic research institutes, and others. Region-wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS • The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets. • It offers a quantitative analysis from 2020 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities. • A comprehensive analysis of four regions is provided to determine the existing opportunities. • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.
KEY MARKET SEGMENTS
By Animal Type • Rat • Mice • Guinea Pigs • Rabbits • Others
By Application • Drug Discovery & Development o Rat o Mice o Guinea Pigs o Rabbits o Others • Basic Research o Rat o Mice o Guinea Pigs o Rabbits o Others • Others o Rat o Mice o Guinea Pigs o Rabbits o Others
By End User • Pharma & Biotech Companies • Academic Research Institutes • Others
By Region • North America o U.S. o Canada o Mexico • Europe o Germany o France o UK o Italy o Spain o Rest of Europe • Asia-Pacific o Japan o China o India o Australia o South Korea o Rest of Asia-Pacific • LAMEA o Brazil o Saudi Arabia o South Africa o Rest of LAMEA
LIST OF KEY PLAYERS PROFILED IN THE REPORT • Charles River Laboratories International, Inc • Envigo • Eurofins Scientific SE • GenOway S.A. • Hera BioLabs (Transposagen Biopharmaceuticals) • JSR Corporation (Crown Bioscience Inc.) • Ozgene Pty Ltd. • PerkinElmer, Inc. (Horizon Discovery Group plc.) • Taconic Biosciences • The Jackson Laboratory
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request.) • PharmaLegacy • Trans Genic Inc, Ltd • Cyagen Biosciences
Our reports have been used by over 10K customers, including:
Global Coronavirus Partnering 2014 to 2021 provides the full collection of Coronavirus disease deals signed between the world’s pharmaceutical and biotechnology companies since 2014. Trends in Coronavirus partnering deals Financial deal terms for headline, upfront and royalty by stage of development Coronavirus...
Global PDGFR Inhibitors Market, Drug Sales & Clinical Trials Insight 2026 Report Analysis & Data Highlights: • Research Methodology • Global & Regional Market Analysis • Global PDGFR Inhibitors Market Opportunity Assessment: > USD 4 Billion • Market & Drug Sales Insight 2020 Till 2026 •...
120 pages •
By Infiniti Research Limited
• Aug 2021
Global Mycoplasma Testing Market 2021-2025 The analyst has been monitoring the mycoplasma testing market and it is poised to grow by $ 496.87 mn during 2021-2025, progressing at a CAGR of over 11% during the forecast period. Our report on the mycoplasma testing market provides a holistic analysis, market size and forecast,...
The global prepacked chromatography columns market reached a value of US$ 2.24 Billion in 2020. Looking forward, the analyst expects the market to grow at a CAGR of 3.5% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on...
The Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2021 report. The report provides a detailed understanding and analysis of how, why and on what terms companies enter discovery stage partnering deals. These deals are discovery stage whereby the licensee obtains a right or an option...
Cholesteryl Ester Transfer Protein - Drugs In Development, 2021 Summary According to the recently published report ’Cholesteryl Ester Transfer Protein - Drugs In Development, 2021’; Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) pipeline Target constitutes close to 6 molecules....
The custom antibody market in Middle East and Africa is expected to grow from US$ 14.0 million in 2021 to US$ 25.0 million by 2028; it is estimated to grow at a CAGR of 8.6% from 2021 to 2028. Growing support from governments, continuously changing disease profiles, rising public–private partnerships, and increasing funding activities are...
Gastric Inhibitory Polypeptide Receptor - Drugs In Development, 2021 Summary Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) pipeline Target constitutes close to 26 molecules. Out of which approximately 23 molecules are developed by companies...
The Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2021 report provides comprehensive understanding and unprecedented access to the co-promotion and co-marketing partnering agreements entered into by the worlds leading biopharma companies. This report provides...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.